Meeting
2013 Gastrointestinal Cancers Symposium
A single-center experience of modified FOLFOX-6 in locally advanced and metastatic pancreatic adenocarcinomas.
Authors
Bradley Sumrall
Ochiner Medical Center
Bradley Sumrall , Chang O Son , Jyotsna Fuloria , Suma Satti
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 31, 2013 (suppl 4; abstr303)
DOI
10.1200/jco.2013.31.4_suppl.303
Abstract #
303
Poster Bd #
C51
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
EndoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas failed on FOLFIRINOX treatment (NCT03126435).
First Author: Li-Tzong Chen
Poster
2019 Gastrointestinal Cancers Symposium
FOLFIRINOX in pancreatic cancer patients age 75 years or older.
First Author: Jonathan Mizrahi
Poster
2018 Gastrointestinal Cancers Symposium
Retrospective single center review of toxicity and efficacy of a modified FOLFIRINOX regimen in patients with locally advanced and metastatic pancreatic cancer.
First Author: Bhargavi Pulluri
Poster
2017 Gastrointestinal Cancers Symposium
5-fluorouracil, oxaliplatin and dasatinib (FOLFOX-D) for previously untreated metastatic pancreatic adenocarcinoma.
First Author: Thomas J. George Jr.